{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T22:38:58Z","timestamp":1788388738880,"version":"build-2803163510"},"reference-count":38,"publisher":"Deutscher Arzte-Verlag GmbH","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"DOI":"10.3238\/arztebl.2019.0445","type":"journal-article","created":{"date-parts":[[2019,6,21]],"date-time":"2019-06-21T08:02:43Z","timestamp":1561104163000},"source":"Crossref","is-referenced-by-count":17,"title":["The Use of Rapid Tranquilization in Aggressive Behavior"],"prefix":"10.3238","author":[{"given":"Sophie","family":"Hirsch","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tilman","family":"Steinert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"11437","published-online":{"date-parts":[[2019,6,28]]},"reference":[{"key":"10.3238\/arztebl.2019.0445_ref1","doi-asserted-by":"crossref","unstructured":"Pajonk FG, Schmitt P, Biedler A, et al.: Psychiatric emergencies in prehospital emergency medical systems: a prospective comparison of two urban settings. Gen Hosp Psychiatry 2008; 30: 360\u20136","DOI":"10.1016\/j.genhosppsych.2008.03.005"},{"key":"10.3238\/arztebl.2019.0445_ref2","doi-asserted-by":"crossref","unstructured":"Ketelsen R, Schulz M, Driessen M: Zwangsma\u00dfnahmen im Vergleich an sechs psychiatrischen Abteilungen. Gesundheitswesen 2011; 73: 105\u201311","DOI":"10.1055\/s-0029-1246181"},{"key":"10.3238\/arztebl.2019.0445_ref3","doi-asserted-by":"crossref","unstructured":"Ketelsen R, Zechert C, Driessen M, Schulz M: Characteristics of aggression in the psychiatric hospital and predictors of patients at risk. J Psychiatr Ment Health Nurs 2007; 14: 92\u20139","DOI":"10.1111\/j.1365-2850.2007.01049.x"},{"key":"10.3238\/arztebl.2019.0445_ref4","doi-asserted-by":"crossref","unstructured":"Scaggs TR, Glass DM, Hutchcraft MG, Weir WB: Prehospital ketamine is a safe and effective treatment for excited delirium in a community hospital based EMS system. Prehosp Disaster Med 2016; 31: 563\u20139","DOI":"10.1017\/S1049023X16000662"},{"key":"10.3238\/arztebl.2019.0445_ref5","doi-asserted-by":"crossref","unstructured":"Ho JD, Dawes DM, Nelson RS, et al.: Acidosis and catecholamine evaluation following simulated law enforcement \u201euse of force\u201c encounters. Acad Emerg Med 2010;17: e60\u20138","DOI":"10.1111\/j.1553-2712.2010.00813.x"},{"key":"10.3238\/arztebl.2019.0445_ref6","doi-asserted-by":"crossref","unstructured":"Calver L, Drinkwater V, Isbister GK: A prospective study of high dose sedation for rapid tranquilisation of acute behavioural disturbance in an acute mental health unit. BMC Psychiatry 2013; 13: 225","DOI":"10.1186\/1471-244X-13-225"},{"key":"10.3238\/arztebl.2019.0445_ref7","unstructured":"Deutsche Gesellschaft f\u00fcr Psychiatrie und Psychotherapie, Psychosomatik und Nervenheilkunde e. V. (DGPPN): Verhinderung von Zwang: Pr\u00e4vention und Therapie aggressiven Verhaltens bei Erwachsenen. S3-Leitlinie 2018. AWMF-Registernummer 038\u2013022."},{"key":"10.3238\/arztebl.2019.0445_ref8","doi-asserted-by":"crossref","unstructured":"Berardis D, Fornaro M, Orsolini L, et al.: The role of inhaled loxapine in the reatment of acute agitation in patients with psychiatric disorders: a clinical review. Int J Mol Cell Med 2017; 18","DOI":"10.3390\/ijms18020349"},{"key":"10.3238\/arztebl.2019.0445_ref9","unstructured":"Cester-Martinez A, Cortes-Ramas JA, Borraz-Clares D, Pellicer-Gayarre M: New medical approach to out-of-hospital treatment of psychomotor agitation in psychiatric patients: a report of 14 cases. Emergencias 2017; 29: 182\u20134."},{"key":"10.3238\/arztebl.2019.0445_ref10","doi-asserted-by":"crossref","unstructured":"Linder LM, Ross CA, Weant KA: Ketamine for the acute management of excited delirium and agitation in the prehospital setting. Pharmacotherapy 2018; 38: 139\u201351","DOI":"10.1002\/phar.2060"},{"key":"10.3238\/arztebl.2019.0445_ref11","doi-asserted-by":"crossref","unstructured":"Huf G, Alexander J, Gandhi P, Allen MH: Haloperidol plus promethazine for psychosis-induced aggression. Cochrane Database Syst Rev 2016; 11: CD005146","DOI":"10.1002\/14651858.CD005146.pub3"},{"key":"10.3238\/arztebl.2019.0445_ref12","doi-asserted-by":"crossref","unstructured":". Ostinelli EG, Jajawi S, Spyridi S, Sayal K, Jayaram MB: Aripiprazole (intramuscular) for psychosis-induced aggression or agitation (rapid tranquillisation). Cochrane Database Syst Rev 2018; 1: CD008074","DOI":"10.1002\/14651858.CD008074.pub2"},{"key":"10.3238\/arztebl.2019.0445_ref13","doi-asserted-by":"crossref","unstructured":"Belgamwar RB, Fenton M: Olanzapine IM or velotab for acutely disturbed\/agitated people with suspected serious mental illnesses. Cochrane Database Syst Rev 2005; 2: CD003729","DOI":"10.1002\/14651858.CD003729.pub2"},{"key":"10.3238\/arztebl.2019.0445_ref14","doi-asserted-by":"crossref","unstructured":"Ostinelli EG, Brooke-Powney MJ, Li X, Adams CE: Haloperidol for psychosis-induced aggression or agitation (rapid tranquillisation). Cochrane Database Syst Rev 2017; 7: CD009377","DOI":"10.1002\/14651858.CD009377.pub3"},{"key":"10.3238\/arztebl.2019.0445_ref15","doi-asserted-by":"crossref","unstructured":"Jayakody K, Gibson RC, Kumar A, Gunadasa S: Zuclopenthixol acetate for acute schizophrenia and similar serious mental illnesses. Cochrane Database Syst Rev 2012; 4: CD000525","DOI":"10.1002\/14651858.CD000525.pub3"},{"key":"10.3238\/arztebl.2019.0445_ref16","doi-asserted-by":"crossref","unstructured":"Zaman H, Sampson SJ, Beck ALS, et al.: Benzodiazepines for psychosis-induced aggression or agitation. Cochrane Database Syst Rev 2017; 12: CD003079.","DOI":"10.1002\/14651858.CD003079.pub4"},{"key":"10.3238\/arztebl.2019.0445_ref17","doi-asserted-by":"crossref","unstructured":"Baldacara L, Sanches M, Cordeiro DC, Jackoswski AP: Rapid tranquilization for agitated patients in emergency psychiatric rooms: a randomized trial of olanzapine, ziprasidone, haloperidol plus promethazine, haloperidol plus midazolam and haloperidol alone. Braz J Psychiatry 2011; 33: 30\u20139","DOI":"10.1590\/S1516-44462011000100008"},{"key":"10.3238\/arztebl.2019.0445_ref18","doi-asserted-by":"crossref","unstructured":"Citrome L: Comparison of intramuscular ziprasidone, olanzapine, or aripiprazole for agitation: a quantitative review of efficacy and safety. J Clin Psychiatry 2007; 68: 1876\u201385","DOI":"10.4088\/JCP.v68n1207"},{"key":"10.3238\/arztebl.2019.0445_ref19","doi-asserted-by":"crossref","unstructured":"Lieberman JA, Stroup TS, McEvoy JP, et al.: Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005; 353: 1209\u201323","DOI":"10.1056\/NEJMoa051688"},{"key":"10.3238\/arztebl.2019.0445_ref20","doi-asserted-by":"crossref","unstructured":"Kittipeerachon M, Chaichan W: Intramuscular olanzapine versus intramuscular aripiprazole for the treatment of agitation in patients with schizophrenia: a pragmatic double-blind randomized trial. Schizophr Res 176: 231\u20138","DOI":"10.1016\/j.schres.2016.07.017"},{"key":"10.3238\/arztebl.2019.0445_ref21","doi-asserted-by":"crossref","unstructured":"Kishi T, Matsunaga S, Iwata N: Intramuscular olanzapine for agitated patients: a systematic review and meta-analysis of randomized controlled trials. J Psychiatr Res 2015; 68: 198\u2013209","DOI":"10.1016\/j.jpsychires.2015.07.005"},{"key":"10.3238\/arztebl.2019.0445_ref22","doi-asserted-by":"crossref","unstructured":"Marder SR, Sorsaburu S, Dunayevich E: Case reports of postmarketing adverse event experiences with olanzapine intramuscular treatment in patients with agitation. J Clin Psychiatry 2010; 71: 433\u201341","DOI":"10.4088\/JCP.08m04411gry"},{"key":"10.3238\/arztebl.2019.0445_ref23","doi-asserted-by":"crossref","unstructured":"Wilson MP, MacDonald K, Vilke GM, Feifel D: A comparison of the safety of olanzapine and haloperidol in combination with benzodiazepines in emergency department patients with acute agitation. J Emerg Med 2012; 43: 790\u20137","DOI":"10.1016\/j.jemermed.2011.01.024"},{"key":"10.3238\/arztebl.2019.0445_ref24","doi-asserted-by":"crossref","unstructured":"Allen MH, Currier GW: Use of restraints and pharmacotherapy in academic psychiatric emergency services. General Hospital Psychiatry 2004; 26; 42\u20139","DOI":"10.1016\/j.genhosppsych.2003.08.002"},{"key":"10.3238\/arztebl.2019.0445_ref25","doi-asserted-by":"crossref","unstructured":"Albrecht B, Staiger PK, Hall K, Miller P, Best D, Lubman DI: Benzodiazepine use and aggressive behaviour: a systematic review. Aust N Z J Psychiatry 2014; 48: 1096\u201314","DOI":"10.1177\/0004867414548902"},{"key":"10.3238\/arztebl.2019.0445_ref26","doi-asserted-by":"crossref","unstructured":"Bieniek SA, Ownby RL, Penalver A, Dominguez RA: A double-blind study of lorazepam versus the combination of haloperidol and lorazepam in managing agitation. Pharmacotherapy 1998; 18: 57\u201362.","DOI":"10.1002\/j.1875-9114.1998.tb03827.x"},{"key":"10.3238\/arztebl.2019.0445_ref27","doi-asserted-by":"crossref","unstructured":"O\u2018Connor L, Rebesco M, Robinson C, et al.: Outcomes of prehospital chemical sedation with ketamine versus haloperidol and benzodiazepine or physical restraint only. Prehosp Emerg Care 2018; 1\u20139.","DOI":"10.1080\/10903127.2018.1501445"},{"key":"10.3238\/arztebl.2019.0445_ref28","doi-asserted-by":"crossref","unstructured":"Currier GW, Chou JCY, Feifel D, et al.: Acute treatment of psychotic agitation: a randomized comparison of oral treatment with risperidone and lorazepam versus intramuscular treatment with haloperidol and lorazepam. J Clin Psychiatry 2004; 65: 386\u201394","DOI":"10.4088\/JCP.v65n0315"},{"key":"10.3238\/arztebl.2019.0445_ref29","doi-asserted-by":"crossref","unstructured":"Hsu WY, Huang SS, Lee BS, Chiu NY: Comparison of intramuscular olanzapine, orally disintegrating olanzapine tablets, oral risperidone solution, and intramuscular haloperidol in the management of acute agitation in an acute care psychiatric ward in Taiwan. J Clin Psychopharmacol 2010; 30: 230\u20134","DOI":"10.1097\/JCP.0b013e3181db8715"},{"key":"10.3238\/arztebl.2019.0445_ref30","doi-asserted-by":"crossref","unstructured":"Walther S, Moggi F, Horn H, et al.: Rapid tranquilization of severely agitated patients with schizophrenia spectrum disorders: a naturalistic, rater-blinded, randomized, controlled study with oral haloperidol, risperidone, and olanzapine. J Clin Psychopharmacol 2014; 34: 124\u20138","DOI":"10.1097\/JCP.0000000000000050"},{"key":"10.3238\/arztebl.2019.0445_ref31","doi-asserted-by":"crossref","unstructured":"Mullinax S, Shokraneh F, Wilson MP, Adams CE: Oral medication for agitation of psychiatric origin: a scoping review of randomized controlled trials. J Emerg Med 2017; 53: 524\u20139","DOI":"10.1016\/j.jemermed.2017.04.026"},{"key":"10.3238\/arztebl.2019.0445_ref32","doi-asserted-by":"crossref","unstructured":"Pratts M, Citrome L, Grant W, Leso L, Opler LA: A single-dose, randomized, double-blind, placebo-controlled trial of sublingual asenapine for acute agitation. Acta Psychiatr Scand 2014; 130: 61\u20138","DOI":"10.1111\/acps.12262"},{"key":"10.3238\/arztebl.2019.0445_ref33","doi-asserted-by":"crossref","unstructured":"Roncero C, Ros-Cucurull E, Palma-Alvarez RF, et al.: Inhaled loxapine for agitation in intoxicated patients: a case series. Clin Neuropharmacol 2017; 40: 281\u20135","DOI":"10.1097\/WNF.0000000000000252"},{"key":"10.3238\/arztebl.2019.0445_ref34","doi-asserted-by":"crossref","unstructured":"Steinert T, Hamann K: External validity of studies on aggressive behavior in patients with schizophrenia: systematic review. CP & EMH; 2012; 8: 74\u201380","DOI":"10.2174\/1745017901208010074"},{"key":"10.3238\/arztebl.2019.0445_ref35","doi-asserted-by":"crossref","unstructured":"Bauer JO, Stenborg D, Lodahl T, Monsted MM: Treatment of agitation in the acute psychiatric setting. An observational study of the effectiveness of intramuscular psychotropic medication. Nord J Psychiatry 2016; 70: 599\u2013605","DOI":"10.1080\/08039488.2016.1188982"},{"key":"10.3238\/arztebl.2019.0445_ref36","unstructured":"neuraxpharm Arzneimittel GmbH: Fachinformation f\u00fcr Haloperidol-neuraxpharm Injektionsl\u00f6sung. Stand: Januar 2018. Langenfeld: neuraxpharm Arzneimittel GmbH. Zulassungsnummer 7819.00.02. www.fachinfo.de\/suche\/fi\/021365 (last accessed on 17 March 2019)."},{"key":"10.3238\/arztebl.2019.0445_ref37","unstructured":"Lilly Deutschland: Fachinformation f\u00fcr ZYPREXA 10 mg Pulver. Stand: November 2018. Bad Homburg: Lilly Deutschland GmbH. EU\/1\/96\/022\/016. www.fachinfo.de\/suche\/fi\/004447 (last accessed on 17 March 2019)."},{"key":"10.3238\/arztebl.2019.0445_ref38","unstructured":"Pfizer Pharma PFE GmbH: Fachinformation f\u00fcr ZELDOX 20 mg\/ml, Pulver und L\u00f6sungsmittel zur Herstellung einer Injektionsl\u00f6sung. Stand: November 2016. Berlin: PFIZER PHARMA PFE GmbH. Zulassungsnummer: 53092.00.00. www.fachinfo.de\/suche\/fi\/005810 (last accessed on 16 May 2019)."}],"container-title":["Deutsches \u00c4rzteblatt international"],"original-title":[],"link":[{"URL":"https:\/\/www.aerzteblatt.de\/10.3238\/arztebl.2019.0445","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,6]],"date-time":"2021-12-06T10:12:33Z","timestamp":1638785553000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.aerzteblatt.de\/10.3238\/arztebl.2019.0445"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6,28]]},"references-count":38,"URL":"https:\/\/doi.org\/10.3238\/arztebl.2019.0445","relation":{},"ISSN":["1866-0452"],"issn-type":[{"value":"1866-0452","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,6,28]]}}}